To compare the infectious complications that occurred during trials of immunomodulatory agents in patients with the acquired immunodeficiency syndrome (AIDS).
Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-gamma.